| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on August 1, 2002; DOI 10.1182/blood-2002-01-0229.
Submitted January 25, 2002
CNRGS, Institut National de la Transfusion Sanguine, Paris, France; INSERM U76, Paris, France * Corresponding author; email: pirenne{at}ints.fr.
The molecular backgrounds of variants encountered in Afro-Caribbean Black individuals and associated to the production of clinically significant antibodies against high-incidence antigens (anti-RH18, anti-RH34) and against Rhe epitopes were determined. We showed that RH:-18 phenotypes are produced by 3 distinct RHCE alleles : ceEK carrying 48G>C (exon 1), 712A>G, 787A>G, 800T>A (exon 5), ceBI carrying 48G>C (exon 1), 712A>G (exon 5), 818C>T (exon 6), 1132C>G (exon 8) and the already known ceAR allele carrying 48G>C (exon 1), 712A>G, 733C>G, 787A>G, 800T>A (exon 5), 916A>G (exon 6). The RH:-34 phenotype is produced by the (C)ces haplotype described previously and composed of an hybrid D-CE(3-8)-D gene with 4 extra-mutations next to a ces allele (733C>G; exon 5) with an extra-mutation in exon 7 (1006G>T). Partial Rhe with risk of immunization against lacking epitopes can be produced by the new ces allele carrying an extra-mutation in exon 3 (340C>T) and by the ceMO allele described previously. A population of sickle cell disease patients was screened to estimate the incidence of these rare alleles with the conclusion that a procedure is required to detect the associated phenotypes in Black donors in order to ensure transfusion safety for patients. We also described a new variant (ces(748)) and variants carrying different altered alleles in non immunized patients and for whom the risk of immunization is discussed.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||